Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Travere Therapeutics Inc. Common Stock — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.45 (market cap $114.26B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) is far larger — about 23.4× Travere Therapeutics Inc. Common Stock's market cap, and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) pays a 1.73% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 3 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ITUB | TVTX | |
|---|---|---|
Market Cap | $114.26B | $4.88B |
Volume | 41,905,072 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $10.16 | $67.52 |
52-Week Low | $6.86 | $26.79 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $1.34T | $5.01B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITUB trades at $9.89, down 1.69% today, following recent profit-taking after reaching 52-week highs. The stock shows bullish technical momentum with strong moving average signals, though RSI indicates overbought conditions. Fundamentally, the bank maintains robust profitability with 27.65% net margin and 21.97% ROE, though recent quarters have seen earnings misses. The company recently received preliminary US bank charter approval, expanding its wealth management services for Latin American clients.
Outlook remains cautiously optimistic with analyst consensus at Buy (46%) and price target of $9.80. Key opportunities include US expansion and strong Brazilian market position, while risks include Brazil's high risk-free rate, competitive pressures, and earnings consistency concerns. The stock trades near fair value with P/E of 11.75 and P/B of 2.5.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)
Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.
Read more on ITUB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
